Leuprolide (Lupron, Lupron Depot)


  • Hormonal


  • Luteinizing hormone-releasing hormone (LH-RH) agonist, inhibits gonadotropin secretion


  • Advanced prostatic cancer

  • Central precocious puberty

  • Endometriosis

  • Uterine fibroids


  • Pregnancy and lactation

  • Undiagnosed vaginal bleeding

  • 30mg depot formulation is contraindicated in women


  • Pregnancy category X

  • Increase in occurrence of disease (prostatic and endometriosis) during initial phases of treatment.

  • May cause bone density changes

Adverse Reactions (Side Effects):

  • ECG changes and ischemia (19.4%)

  • Injection site irritation (13.8%)

  • Edema (12.2%)

  • Hot flashes and sweating (47-84%)

  • Generalized pain (6-32%)

  • Decrease in testicular size  


  • Administered by injection

  • Advanced prostatic cancer: 1mg SQ daily or 7.5mg IM monthly or 22.5mg IM every three months or 30mg IM every four months

  • Central precocious puberty: individualize dose per patient based on weight

  • < 25kg = 7.5mg IM every four weeks

  • 25-37.5kg = 11.25mg IM every four weeks

  • >37.5kg = 15mg IM every four weeks

  • Endometriosis: 3.75mg IM monthly or 11.25mg IM every three months

  • Uterine fibroids: recommended therapy less than 3 months

  • 3.75mg IM monthly or 11.25mg IM once for three months

Back to Medical Corps Pharmacy Page